India Globalization Capital Inc Total Assets
India Globalization Capital Inc total assets. Based on the latest financial reports, India Globalization Capital Inc (IGC) holds total assets worth $9.74 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see IGC market cap for the company's overall valuation and market capitalisation.
Total Assets of India Globalization Capital Inc (2006–2025)
Total assets of India Globalization Capital Inc from 2006 to 2025. This chart illustrates how India Globalization Capital Inc's total assets have evolved over time, based on quarterly financial data. See IGC stock price for real-time trading data and today's change.
India Globalization Capital Inc - Asset Composition Analysis
India Globalization Capital Inc Total Assets Breakdown (March 2025)
India Globalization Capital Inc total assets breakdown as of March 2025. India Globalization Capital Inc's total assets of $9.74 Million consist of 33.1% current assets and 66.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $405.00K | 4.6% |
| Accounts Receivable | $77.00K | 0.9% |
| Inventory | $1.36 Million | 15.6% |
| Property, Plant & Equipment | $3.32 Million | 37.9% |
| Intangible Assets | $1.85 Million | 21.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how India Globalization Capital Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore IGC current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: India Globalization Capital Inc's current assets represent 33.1% of total assets in 2025, a decrease from 100.0% in 2006.
- Cash Position: Cash and equivalents constituted 4.6% of total assets in 2025, up from 0.0% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 21.0% of total assets, an increase from 0.0% in 2006.
- Asset Diversification: The largest asset category is property, plant & equipment at 37.9% of total assets.
India Globalization Capital Inc Competitors by Total Assets
Key competitors of India Globalization Capital Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
India Globalization Capital Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.32 | 1.52 | 5.95 |
| Quick Ratio | 0.89 | 0.98 | 2.36 |
| Cash Ratio | 0.73 | 0.55 | 0.00 |
| Working Capital | $490.00K | $1.45 Million | $9.50 Million |
India Globalization Capital Inc - Advanced Valuation Insights
This section examines the relationship between India Globalization Capital Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.41 |
| Latest Market Cap to Assets Ratio | 3.08 |
| Asset Growth Rate (YoY) | -11.7% |
| Total Assets | $8.75 Million |
| Market Capitalization | $26.91 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values India Globalization Capital Inc's assets at a significant premium (3.08x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: India Globalization Capital Inc's assets decreased by 11.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for India Globalization Capital Inc (2006–2025)
The table below shows the annual total assets of India Globalization Capital Inc from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $8.75 Million | -11.66% |
| 2024-03-31 | $9.90 Million | -42.36% |
| 2023-03-31 | $17.18 Million | -35.98% |
| 2022-03-31 | $26.83 Million | -25.18% |
| 2021-03-31 | $35.87 Million | +23.75% |
| 2020-03-31 | $28.98 Million | -15.90% |
| 2019-03-31 | $34.47 Million | +217.56% |
| 2018-03-31 | $10.85 Million | -3.82% |
| 2017-03-31 | $11.28 Million | -40.17% |
| 2016-03-31 | $18.86 Million | -7.24% |
| 2015-03-31 | $20.33 Million | +14.64% |
| 2014-03-31 | $17.73 Million | -7.89% |
| 2013-03-31 | $19.25 Million | -23.78% |
| 2012-03-31 | $25.26 Million | +39.08% |
| 2011-03-31 | $18.16 Million | -48.65% |
| 2010-03-31 | $35.37 Million | -31.76% |
| 2009-03-31 | $51.83 Million | -23.36% |
| 2008-03-31 | $67.63 Million | -4.33% |
| 2007-03-31 | $70.69 Million | +7.22% |
| 2006-03-31 | $65.93 Million | -- |
About India Globalization Capital Inc
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer's disease; IGC-1C for the treatm… Read more